With a market cap of around $23 billion, Incyte Corporation (INCY) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics across the United States, Europe, Canada, and Japan. It markets a diverse portfolio of oncology, immunology, and dermatology medicines, including JAKAFI, OPZELURA, and ICLUSIG.
The Wilmington, Delaware-based company is set to unveil its fiscal Q2 2026 results before the market opens on Tuesday, Jul. 28. Ahead of this event, analysts expect INCY to report a profit of $1.61 per share, up 22.9% from $1.31 per share in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on another occasion.